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ABSTRACT
KAMINSKY, L. A., M. P. HARBER, M. T. IMBODEN, R. ARENA, and J. MYERS. Peak Ventilation Reference Standards from
Exercise Testing: From the FRIEND Registry. Med. Sci. Sports Exerc., Vol. 50, No. 12, pp. 2603–2608, 2018. Purpose: Cardiopul-
monary exercise testing (CPX) provides valuable clinical information, including peak ventilation (V˙Epeak), which has been shown to have
diagnostic and prognostic value in the assessment of patients with underlying pulmonary disease. This report provides reference standards for
V˙Epeak derived from CPX on treadmills in apparently healthy individuals. Methods: Nine laboratories in the United States experienced in
CPX administration with established quality control procedures contributed to the Fitness Registry and the Importance of Exercise National
Database from 2014 to 2017. Data from 5232 maximal exercise tests from men and women without cardiovascular or pulmonary disease
were used to create percentiles of V˙Epeak for both men and women by decade between 20 and 79 yr. Additionally, prediction equations were
developed for V˙Epeak using descriptive information. Results: V˙Epeak was found to be significantly different between men and women and
across age groups (P G 0.05). The rate of decline in V˙Epeak was 8.0% per decade for both men and women. A stepwise regression model of
70% of the sample revealed that sex, age, and height were significant predictors of V˙Epeak. The equation was cross-validated with data from
the remaining 30% of the sample with a final equation developed from the full sample (r = 0.73). Additionally, a linear regression model
revealed forced expiratory volume in 1 s significantly predicted V˙Epeak (r = 0.73). Conclusions: Reference standards were developed for
V˙Epeak for the United States population. Cardiopulmonary exercise testing laboratories will be able to provide interpretation of V˙Epeak from
these age and sex-specific percentile reference values or alternatively can use these nonexercise prediction equations incorporating sex, age,
and height or with a single predictor of forced expiratory volume in 1 s. Key Words: CARDIOPULMONARY EXERCISE TESTING,
PREDICTION EQUATIONS, REFERENCE VALUES, APPARENTLY HEALTHY
C
ardiopulmonary exercise testing (CPX) is increas-
ingly being used as a valuable tool in assessing pa-
tients with a variety of chronic diseases (1). Peak
exercise ventilation (V˙Epeak) is a measure obtained from CPX
and is a key component of peak oxygen uptake (V˙O2peak) and
carbon dioxide production (V˙CO2peak). V˙Epeak is also an im-
portant component in the assessment of individuals with
unexplained exertional dyspnea and patients diagnosed with
pulmonary disease. Additionally, V˙E, V˙O2, and V˙CO2 are
further combined and used with other variables such as V˙E/
V˙CO2 slope, exercise oscillatory V˙E pattern, partial pres-
sure of end-tidal CO2, which have been shown to have
both diagnostic and prognostic value in chronic disease
populations (2,3).
The importance of cardiorespiratory fitness (CRF) mea-
sured as V˙O2peak, one of the key variables from CPX, was
promoted in a Policy Statement by the American Heart
Association (4). The need for a national CRF registry was
suggested, because there were no reference standards for
interpretation of VO2peak. This led to the development of
the Fitness Registry for the Importance of Exercise National
Database (FRIEND) which has provided United States based
CRF reference standards for individuals without cardio-
vascular disease (CVD) or chronic obstructive pulmonary
diseases (COPD) (5–7). Recently, the American Heart As-
sociation issued a scientific statement suggesting that CRF
should be considered a vital sign and thus should be
assessed routinely in clinical practice (8). A recent review
and a report on worldwide CRF levels provide additional
support of the importance of CRF (9,10).
V˙Epeak is an important component of V˙O2peak and may be
a limiting factor for exercise capacity for patients with
moderate to severe COPD (11). Generally, if interpreted at
all, V˙Epeak is compared with maximal voluntary ventila-
tion (MVV) and is typically considered normal if the ratio
ranges between 50% and 80% (12). Alternatively, V˙Epeak
is subtracted from MVV to calculate breathing reserve,
with values G15 LIminj1 considered abnormal, indicating a
pulmonary mechanism for abnormally low CRF (13). With
the exception of comprehensive pulmonary function testing
profiles, MVV is rarely measured but rather it is more typical
to predict it from forced expiratory volume in 1 s (FEV1) (14).
Similar to CRF, having reference standards for V˙Epeak are
needed and would aid in the interpretation of this important
CPX variable. Additionally, having reference values of the
V˙Epeak/MVV ratio will provide enhanced opportunities for the
interpretation of the peak ventilation from a CPX result, when
MVV data are available. This will also allow future in-
vestigations to evaluate how V˙Epeak may contribute to the
diagnosis and/or prognosis of patients with chronic diseases,
as well as refine the ability to diagnose a pulmonary limita-
tion to CRF in those with unexplained exertional dyspnea.
Therefore, the purpose of this study was to develop refer-
ence standards for V˙Epeak measurements obtained during CPX
using data from the FRIEND Registry. Additionally, because
V˙Epeak has commonly been interpreted relative to MVV, ref-
erence values of the V˙Epeak/MVV ratio were also developed.
A secondary purpose was to develop simple-regression
equations to predict V˙Epeak: 1) from sex, age, and height if
pulmonary function test results are not available; and 2) from
FEV1 if pulmonary function test results are available.
METHODS
The procedures used for acquiring and managing the data
for FRIEND have been previously reported (5). Briefly,
laboratories contributing to FRIEND provided resting and
CPX data from maximal treadmill protocols using an aver-
age of data during the final 30 to 60 s of the CPX. Local
institutional review board approval for participation in the
FRIEND Registry was obtained by each participating CPX
laboratory to submit deidentified, coded data to the data
coordinating center at Ball State University, which then
forwarded these data to the core CPX laboratory housed at
the University of Illinois at Chicago. Institutional review
board approval for the core CPX laboratory was also
obtained at the University of Illinois at Chicago.
The current analysis includes 5232 tests from the nine
participating CPX laboratories (see acknowledgments) with
geographical representation from seven states including
California, Connecticut, Indiana, Maryland, Missouri, North
Carolina, and Texas. Any subject identified as having a
preexisting diagnosis of CVD or COPD was excluded from
the current analysis. Inclusion criteria included CPX data for
those free from any known CVD and COPD at the time of
testing, as well as: 1) age Q20 yr; 2) maximal exercise test
performed on a treadmill; 3) peak respiratory exchange ratio
value Q1.00. Of these there were 3434 test records that
included a measure of FEV1. For all subjects, FEV1 was
also predicted using the Crapo equations for men and
women (15), and MVV was predicted as both FEV1  35
and FEV1  40 (16,17).
Statistical analysis. Analysis of variance was used to
compare differences in V˙Epeak values between sex and across
age groups. When significant differences were detected by
ANOVA, the Tukey test was used for post hoc analysis.
Regression analyses were used to develop equations for
predicting V˙Epeak using descriptive data available in the
FRIEND data (18). As sex, age, and height have been
established as the primary predictors of spirometry values, a
stepwise regression model was performed with these three
variables in 70% of the sample that was randomly assigned
to the validation group (19). This equation was cross-
validated with data from the remaining 30% of the sample,
with a final equation developed from the full sample (20).
Additionally, for circumstances where FEV1 is available, a
linear regression model was performed with FEV1 as the
sole predictor. Pearson product moment correlations were
computed for the measured and predicted V˙Epeak. The SPSS
24.0 (IBM, Armonk, NY) statistical software package was
used for all analyses. All tests with a P value G0.05 were
considered statistically significant.
RESULTS
The FRIEND cohort for this report included data on 3043
men and 2189 women (Table 1). Table 2 provides V˙Epeak
values, measured during CPX on treadmills, for both men
and women in six decades of age groups. V˙Epeak was sig-
nificantly (P G 0.05) higher for men compared with women
and for each younger age group in both sexes.
FEV1 data, obtained from spirometry was available for
approximately 65% of this cohort and is shown in Table 3.
FEV1 was also predicted from the descriptive data for this
cohort and was used to predict MVV from two commonly
used formulas of multiplying by either 35 or 40 (16,17). The
ratios of V˙Epeak/MVV were calculated using both MVV
equations to assess the range of these values in the FRIEND
cohort. Values 90.8 for V˙Epeak/MVV ratio were observed in
approximately 37% of women and 60% of men when using
FEV1  35 to predict MVV and ~18% of women and 32%
of men if using FEV1  40 (Table 4). Additionally, values
91.0 for V˙Epeak/MVV ratio were observed in ~7% of women
TABLE 1. Descriptive characteristics of the FRIEND cohort.
Men (n = 3043) Women (n = 2189)
Age (yr) 46.4 T 13.5 46.4 T 14.1
V˙Epeak (LImin
j1) 110.9 T 29.2* 71.6 T 19.7
VO2peak (mLIkg
j1Iminj1) 34.0 T 9.6* 26.5 T 7.9
Height (inches) 70.1 T 2.8* 64.5 T 2.6
Weight (kg) 91.0 T 17.7* 74.3 T 18.1
Body mass index (kgImj2) 28.7 T 5.2 27.7 T 6.4
Waist (cm) 98.1 T 14.9* 84.1 T 14.8
Resting HR (bpm) 67 T 12 69 T 10
Maximal HR (bpm) 172 T 18 172 T 17
Resting SBP/DBP (mm Hg) 126/81 T 15/10* 118/74 T 15/10
FEV1 (L) 3.690 T 0.760* 2.696 T 0.573
Data are mean T SD.
*Significantly different between men and women, P G 0.05.
DBP, diastolic blood pressure; SBP, systolic blood pressure.
and 15% of men if using FEV1  35 to predict MVV and
~6% of men if using FEV1  40.
Stepwise multiple regression analyses revealed that sex,
followed by age and then height all made significant con-
tributions to estimating V˙Epeak from the data of the validation
sample group. The equation was found to be accurate be-
cause there was no significant difference between the pre-
dicted and measured V˙Epeak in the cross-validation group
(93.9 T 23.1 vs 93.6 T 31.9 LIminj1; P 9 0.05). The Pearson
correlation coefficient between the predicted and measured
V˙Epeak was 0.74. Given the demonstrated accuracy of the pre-
diction equation from the cross-validation procedure, the
stepwise multiple regression analyses were repeated with the
entire sample to produce the final prediction equation: V˙Epeak
(LIminj1) =17.32–28.33 (sex; men = 0, women = 1) j 0.79
(age [yr]) – 1.85 (height [inches]); SEE = 21.7. The correlation
for the model using the whole sample was r = 0.73. FEV1 is
often available as it may be measured in some laboratories,
thus a linear regression equation (r = 0.73) was developed:
V˙Epeak (LImin
j1) = 5.51 + 26.79 (FEV1 [L]), SEE = 21.6.
DISCUSSION
Although it is generally understood that V˙Epeak is greater
in men than in women and declines with age, there are no
reference values available to interpret V˙Epeak. The data from
the FRIEND registry show that, on average, V˙Epeak is 34%
higher in men than women, and V˙Epeak declines approxi-
mately 8% per decade in both men and women from the 3rd
to 8th decades.
Commonly, if V˙Epeak from CPX is interpreted at all, it is
done so in relationship to MVV, which is then used to deter-
mine breathing reserve (3,12,13). This interpretation typically
considers normal V˙Epeak to be 50% to 80% of MVV. Inter-
estingly, these data from an apparently healthy population
from FRIEND, found more than a third of women and half of
men exceeded the upper end of the range of normal (80%)
using the common estimation of MVV calculated as 35 
FEV1. Compared with another common estimation of MVV
(=40 FEV1) approximately a fifth of the women and a third
of the men from FRIEND exceeded the upper end of the
range of normal. Additionally, 15% of men and 7% of
women had V˙Epeak values greater than MVV (=35  FEV1)
and 6% of men had V˙Epeak values greater than MVV (=40 
FEV1). These findings demonstrate the limitations to using
this approach for interpreting V˙Epeak values.
A more direct approach to interpret V˙Epeak would be to
apply the FRIEND reference standards for V˙Epeak from CPX.
This would be done by comparing the measured V˙Epeak to
that from FRIEND age- and sex-specific reference values for
the means T SD from Table 1 or as a percentile (Table 5).
The interpretation of V˙Epeak as either a percent of predicted
or as a percentile will allow future studies to consider the
importance of this variable as a contributor to existing CPX-
derived diagnostic or prognostic algorithms (3). For exam-
ple, it would be of interest to explore factors related to the
gender differences in V˙Epeak compared to differences in
V˙O2peak. The rate of decline in V˙Epeak is slightly lower (8%
per decade) than that previously shown for V˙O2peak (9.2 and
10.3% per decade for men and women, respectively) from
the FRIEND registry (5). However, the average difference in
V˙Epeak between men and women was slightly higher for
V˙Epeak (34%) than that for V˙O2peak (27%).
Two larger studies from Norway did report mean V˙Epeak
data in their studies focused on CRF (Fig. 1) (21,22). These
studies from the Norwegian cohort_s men and women had
higher V˙O2peak compared with those in the FRIEND reg-
istry and a similar population difference for V˙Epeak was
observed. Mean V˙Epeak values by decade were higher by 11
to 19 LIminj1 and 3 to 14 LIminj1 for men and women,
TABLE 2. Peak ventilation (LIminj1) during CPX data from the FRIEND registry (n = 5232).
Age (yr)* 20–29 30–39 40–49 50–59 60–69 70–79
Men 130 T 30 121 T 25 113 T 25 103 T 25 93 T 24 80 T 24
(n = 3043)** (434) (524) (756) (748) (458) (123)
Women 89 T 21 78 T 19 74 T 16 67 T 15 59 T 14 53 T 12
(n = 2189) (324) (360) (536) (557) (325) (87)
Data are mean T SD.
*P G 0.05 Each age-group different from all other age-groups.
**P G 0.05 Men different from women in each age group.
TABLE 3. FEV1 (L) from the FRIEND registry.
Method Age* (yr) 20–29 30–39 40–49 50–59 60–69 70–79
Measured Men** (n = 1973) 4.17 T 0.81 3.99 T 0.74 3.78 T 0.67 3.51 T 0.65 3.19 T 0.65 2.90 T 0.65
Predicted Men*** (n = 1973) 4.62 T 0.34 4.36 T 0.32 4.11 T 0.30 3.87 T 0.30 3.57 T 0.30 3.31 T 0.32
Predicted Men** (n = 3043) 4.65 T 0.34 4.37 T 0.30 4.11 T 0.29 3.86 T 0.41 3.58 T 0.30 3.32 T 0.30
Measured Women (n = 1461) 3.19 T 0.57 3.00 T 0.52 2.75 T 0.45 2.50 T 0.43 2.24 T 0.42 1.95 T 0.41
Predicted Women***(n = 1461) 3.47 T 0.25 3.19 T 0.23 2.91 T 0.24 2.62 T 0.25 2.35 T 0.22 2.04 T 0.27
Predicted Women (n = 2189) 3.50 T 0.25 3.19 T 0.23 2.92 T 0.24 2.63 T 0.24 2.36 T 0.23 2.07 T 0.25
Data are mean T SD.
*P G 0.05 Each age group different from all other age groups.
**P G 0.05 Men different from women in each age group.
**P G 0.05 Predicted different from measured FEV1 in each age group.
Measured with pulmonary function testing: predicted using Crapo et al equations.
respectively, in the Loe et al. (21) study and higher by 9 to
20 LIminj1 and 2 to 14 LIminj1 for men and women, re-
spectively in the Evadsen et al. (22) study across the six
decades compared with those in the FRIEND cohort. The
Norwegian cohorts also showed a similar rate of decline in
V˙Epeak data with age of 7% to 9% per decade. The difference
in mean values per decade between men and women ranged
between 30 and 39 LIminj1 (~34% higher in men) for
FRIEND and both Norwegian cohorts. Another study of a
small (n = 231) cohort from Canada, with cycle ergometry as
the test mode, showed similar rates of decline with age (8%–
9% per decade) and similar, albeit slightly smaller differences
between men and women (28%) in V˙Epeak (23). Although
there are no other large data sets that have reported V˙Epeak
data, some studies related to exercise training, with small
sample sizes, have included this measure along with V˙O2peak
in their reports. For example, a study of athletes by Saltin and
Astrand reported V˙Emax of 156 T 19 and 112 T 11 LImin
j1 for
15- to 33-yr-old men and women, respectively (24).
Heath et al. (25) compared young and old endurance
trained men with untrained older men. They reported
both the trained younger (n = 16, ages 19–27 yr) and
older subjects (n = 16, 50–72 yr) had similar V˙Emax values of
125 T 17 and 129 T 19 LIminj1, respectively, whereas
untrained older men (n = 16, 51 yr) had an average V˙Emax of
97 LIminj1. Another report by Trappe et al. (26) compared
octogenarian athletic men (n = 8) to untrained men (n = 8). The
mean V˙Emax values were 79 T 3 LImin
j1 and 63 T 6 LIminj1
for these older athletes and untrained men, respectively. This
could suggest that exercise training may provide some pro-
tection against the rate of decline in V˙Emax with age, although
this will need to be explored in future studies.
TABLE 4. Sex-specific percentiles for V˙Epeak/MVV ratio. V˙E from CPX obtained from the FRIEND registry and MVV estimated from FEV1 35 [A] and from FEV1 40 [B].
Age Groups (yr)/Percentiles 5 10 25 50 75 90 95
A
Men
20–29 0.40 0.51 0.61 0.71 0.81 0.88 0.93
30–39 0.45 0.53 0.61 0.70 0.78 0.87 0.91
40–49 0.44 0.48 0.59 0.69 0.79 0.89 0.93
50–59 0.42 0.48 0.56 0.67 0.77 0.88 0.94
60–69 0.40 0.46 0.55 0.64 0.75 0.84 0.91
70–79 0.36 0.40 0.50 0.59 0.71 0.85 0.94
Women
20–29 0.40 0.45 0.53 0.64 0.73 0.82 0.86
30–39 0.37 0.42 0.50 0.61 0.71 0.81 0.88
40–49 0.42 0.46 0.53 0.63 0.73 0.81 0.86
50–59 0.41 0.45 0.54 0.63 0.73 0.81 0.87
60–69 0.41 0.45 0.53 0.62 0.72 0.80 0.86
70–79 0.43 0.47 0.55 0.65 0.76 0.84 0.90
B
Men
20–29 0.46 0.58 0.70 0.81 0.92 1.00 1.06
30–39 0.52 0.61 0.69 0.80 0.90 0.99 1.04
40–49 0.50 0.55 0.68 0.79 0.90 1.02 1.06
50–59 0.48 0.55 0.64 0.76 0.88 1.00 1.07
60–69 0.45 0.52 0.62 0.73 0.86 0.96 1.03
70–79 0.41 0.46 0.57 0.67 0.81 0.98 1.07
Women
20–29 0.45 0.51 0.61 0.73 0.84 0.94 0.99
30–39 0.42 0.48 0.57 0.69 0.81 0.93 1.01
40–49 0.48 0.52 0.61 0.72 0.83 0.93 0.99
50–59 0.47 0.52 0.62 0.72 0.84 0.92 1.00
60–69 0.47 0.52 0.61 0.71 0.83 0.92 0.98
70–79 0.49 0.53 0.63 0.74 0.86 0.96 1.02
TABLE 5. Sex-specific percentiles for peak treadmill exercise ventilation (LIminj1) from CPX obtained from the FRIEND registry.
Age Groups (yr)/Percentiles 5 10 25 50 75 90 95
A. Men
20–29 72 89 113 132 151 168 176
30–39 79 93 106 121 137 152 162
40–49 72 81 96 114 130 146 156
50–59 63 73 86 102 120 136 145
60–69 55 64 77 91 108 122 130
70–79 45 50 63 76 90 115 129
B. Women
20–29 53 60 74 89 103 116 122
30–39 48 53 63 76 91 105 111
40–49 46 52 62 74 85 94 101
50–59 44 47 56 65 76 86 93
60–69 39 42 49 58 69 78 79
70–79 33 36 45 52 63 68 75
All subjects were considered free from known CVD and COPD.
Common to studies using retrospective data, there are some
limitations that should be considered. Subjects with previously
diagnosed CVD and COPD were excluded from this data set.
However, the population did have some chronic diseases (e.g.,
diabetes, obesity) and musculoskeletal concerns (e.g., back
pain, osteoarthritis). Although all tests were performed for
functional capacity measurement, the individual referral for the
tests varied (clinical assessment, fitness screening, and research
evaluation). Additionally, the choice of test protocols (~56%
with ramp type and 45% with incremental type), measurement
equipment, and data collection procedures although consistent
with recommendations provided in recently published guide-
lines, was specific to each contributing laboratory (1,27,28).
These reference standards from FRIEND provide an alter-
native for investigators to derive an estimation of expected
values for V˙Epeak for men and women from CPX (Table 4).
Alternatively, estimates of V˙Epeak could be obtained using the
regression equation incorporating sex, age, and height or with
the simple equation with FEV1 as the sole predictor. This
simple equation, which could be an easy to remember rule of
thumb (V˙Epeak = [FEV1  27] + 5), may be helpful in clinical
practice. This approach would allow interpretation of the
measured value as a percentage of predicted.
CONCLUSIONS
Reference standards for V˙Epeak were established from the
FRIEND Registry from CPX data in the United States. These
standards can be applied for the interpretation of V˙Epeak along
with other measures obtained in CPX. Future studies should
explore the potential contribution of individuals V˙Epeak re-
sponse related to health and disease outcomes. Additionally,
factors that may influence V˙Epeak and its change with age,
such as exercise training should be explored.
FRIEND Consortium Contributors: Ball State University (Leonard
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The results of the study are presented clearly, honestly, and
without fabrication, falsification, or inappropriate data manipulation,
and statement that results of the present study do not constitute
endorsement by ACSM.
L. K.: The project described was partially supported by TKC Global
through Grant No. GS04T11BFP0001 to Ball State University and L. K.
serves as a Scientific Advisor for ENDO Medical, Inc. The content is
solely the responsibility of the authors and does not necessarily rep-
resent the official views of the National Institutes of Health. M. Harber,
M. Imboden, R. Arena, and J. Myers: nothing to disclose.
REFERENCES
1. Balady GJ, Arena R, Sietsema K, et al. Clinician’s guide to car-
diopulmonary exercise testing in adults: a scientific statement from
the American Heart Association. Circulation. 2010;122:191–225.
2. Guazzi M, Adams V, Conraads V, et al. Clinical recommendations
for cardiopulmonary exercise testing data assessment in specific
patient populations. Circulation. 2012;126:2261–74.
3. Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavie CJ. 2016
Focused update: clinical recommendations for cardiopulmonary
exercise testing data assessment in specific patient populations.
Circulation. 2016;133:e694–711.
4. Kaminsky LA, Arena R, Beckie TM, et al. American Heart Asso-
ciation Advocacy Coordinating Committee, Council on Clinical
Cardiology, and Council on Nutrition, Physical Activity and Me-
tabolism. The importance of cardiorespiratory fitness in the United
States: the need for a national registry: a policy statement from the
American Heart Association. Circulation. 2013;127:652–62.
5. Kaminsky LA, Arena R, Myers J. Reference standards for car-
diorespiratory fitness measured with cardiopulmonary exercise
testing: data from the fitness registry and the importance of exer-
cise national database. Mayo Clin Proc. 2015;90:1515–23.
FIGURE 1—Peak ventilation (LIminj1) during cardiopulmonary testing data for men and women from three previous studies (11–13).
6. Kaminsky LA, Imboden MT, Arena R, Myers J. Reference stan-
dards for Cardiorespiratory fitness measured with cardiopulmonary
exercise testing using cycle ergometry: data from the fitness reg-
istry and the importance of exercise National Database (FRIEND)
registry. Mayo Clin Proc. 2017;92:228–33.
7. Myers J, Kaminsky LA, Lima R, Christle JW, Ashley E, Arena R.
A reference equation for normal standards for VO2 max: analysis
from the Fitness Registry and the Importance of Exercise National
Database (FRIEND registry). Prog Cardiovasc Dis. 2017;60:21–9.
8. Ross R, Blair SN, Arena R, et al. Importance of assessing cardio-
respiratory fitness in clinical practice: a case for fitness as a clinical
vital sign: a scientific statement from the American Heart Associ-
ation. Circulation. 2016;134:e653–99.
9. Harber MP, Kaminsky LA, Arena R, et al. Impact of cardiorespi-
ratory fitness on all-cause and disease-specific mortality: advances
since 2009. Prog Cardiovasc Dis. 2017;60:11–20.
10. Nauman J, Tauschek LC, Kaminsky LA, Nes BM, WislLff U.
Global fitness levels: findings from a web-based surveillance re-
port. Prog Cardiovasc Dis. 2017;60(1):78–88.
11. Killian KJ, Leblanc P, Martin DH, Summers E, Jones NL,
Campbell EJ. Exercise capacity and ventilatory, circulatory, and
symptom limitation in patients with chronic airflow limitation. Am
Rev Respir Dis. 1992;146:935–40.
12. Hansen JE, Sue DY, Wasserman K. Predicted values for clinical
exercise testing. Am Rev Respir Dis. 1984;129(2 Pt 2):S49–54.
13. Wasserman K, Hansen JE, Sue DY, Whipp BJ, Casaburi R. Principles
of Exercise Testing and Interpretation. 2nd ed. Philadelphia: Lea &
Febiger; 1994. p. 124.
14. Miller MR, Hankinson V, Brusasco F, et al. Standardization of
lung function testing. Eur Respir J. 2005;26:319–38.
15. Crapo RO, Morris AH, Gardner RM. Reference spirometric values
using techniques and equipment that meet ATS recommendations.
Am Rev Respir Dis. 1981;123:659–64.
16. Cotes JE. Lung Function: Assessment and Application in Medicine.
3rd ed. Oxford: Blackwell Scientific Publications; 1975. p. 104.
17. Gandevia B, Hugh-Jones P. Terminology for measurements of
ventilatory capacity; a report to the thoracic society. Thorax. 1957;12:
290–3.
18. Pedhazur EJ, Schmelkin LP. Measurement, Design, and Analysis:
An Integrated Approach. Hillsdale: Lawrence Erlbaum Associates,
Publishers; 1991. p. 433.
19. U.S. Department of Labor. Spirometry prediction tables for normal
males and females. Occupational safety and health standards. 1910.
1043 App C. Assessed on July 15, 2018: https://www.osha.gov/pls/
oshaweb/owadisp.show_document?p_table=STANDARDS&p_
id=10058.
20. Palmer PB, O’Connell DG. Regression analysis for prediction: un-
derstanding the process. Cardiopulm Phys Ther J. 2009;20:23–6.
21. Loe H, Rognmo K, Saltin B, WislLff U. Aerobic capacity reference
data in 3816 healthy men and women 20-90 years. PLoS One.
2013;8:e64319.
22. Edvardsen E, Scient C, Hansen BH, Holme IM, Dyrstad SM,
Anderssen SA. Reference values for cardiorespiratory response
and fitness on the treadmill in a 20- to 85-year-old population.
Chest. 2013;144:241–8.
23. Blackie SP, Fairbarn MS, McElvaney NG, et al. Chest. 100:136–42.
24. Saltin B, Astrand PO. Maximal oxygen uptake in athletes. J Appl
Physiol. 1967;23:353–8.
25. Heath GW, Hagberg JM, Ehsani AA, Holloszy JO. A physiologi-
cal comparison of young and older endurance athletes. J Appl
Physiol Respir Environ Exerc Physiol. 1981;51:634–40.
26. Trappe S, Hayes E, Galpin A, et al. New records in aerobic power
among octogenarian lifelong endurance athletes. J Appl Physiol
(1985). 2013;114:3–10.
27. Myers J, Arena R, Franklin B, et al. Recommendations for clinical
exercise laboratories: a scientific statement from the American
Heart Association. Circulation. 2009;119(24):3144–61.
28. Myers J, Forman DE, Balady GJ, et al. Supervision of exercise
testing by nonphysicians: a scientific statement from the American
Heart Association. Circulation. 2014;130(12):1014–27.
